Cerus Corporation Announces Public Offering of Common Stock
January 28 2020 - 4:01PM
Business Wire
Cerus Corporation (Nasdaq: CERS) announced today that it has
commenced a registered underwritten public offering of $50.0
million of its common stock. In addition, Cerus expects to grant
the underwriter a 30-day option to purchase up to an additional
$7.5 million of its common stock. All of the shares to be sold in
the offering are to be sold by Cerus.
BTIG, LLC is acting as sole book-running manager for the
offering.
A shelf registration statement on Form S-3 (File No. 333-219727)
relating to the shares of common stock described above was
previously filed by Cerus with the Securities and Exchange
Commission ("SEC") and declared effective on January 8, 2018. A
preliminary prospectus supplement related to the offering will be
filed with the SEC. Prospective investors should read the
preliminary prospectus supplement, when available, and the
accompanying prospectus and other documents Cerus has filed with
the SEC for more complete information about Cerus and the proposed
offering. These documents are available at no charge by visiting
the SEC's website at http://www.sec.gov. Alternatively, copies of
the preliminary prospectus supplement, when available, and the
accompanying prospectus may be obtained by contacting BTIG, LLC at
65 East 55th Street, New York, NY, 10022, by email at
equitycapitalmarkets@btig.com or by telephone at (212)
593-7555.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any
such state or jurisdiction.
About Cerus
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply. Based in Concord, California, Cerus develops
and markets the INTERCEPT Blood System. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world.
Forward Looking Statements
This press release contains forward-looking statements. Any
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements,
including, without limitation, statements relating to the
completion, timing and size of Cerus’ public offering. These
forward-looking statements are based upon Cerus’ current
expectations. Actual results could differ materially from these
forward-looking statements as a result of certain factors,
including, without limitation, risks related to completion of the
proposed public offering on the anticipated terms, if at all,
market conditions and the satisfaction of customary closing
conditions related to the public offering, risks related to the
application of the net proceeds from the public offering, risks
associated with the uncertain research and product development
process, and other risks detailed in Cerus' filings with the SEC,
including in Cerus' quarterly report on Form 10-Q for the quarter
ended September 30, 2019, filed with the SEC on October 30, 2019
and in the preliminary prospectus supplement related to the public
offering to be filed with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Cerus does not undertake
any obligation to update any forward-looking statements as a result
of new information, future events, changed assumptions or
otherwise
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200128005746/en/
Tim Lee – Investor Relations Director Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2023 to Apr 2024